Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure ##STR1## wherein R.sup.1 to R.sup.7, Q, X and Y are as defined herein.
Claims What is claimed is: 1. A compound which has the structure ##STR701## where Q is ##STR702## R.sup.1 is a fluorenyl-type group of the structure ##STR703## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O, S, ##STR704## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylenealkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, heteroaryl, heteroarylalkyl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the provisos that (1) when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR705## or a bond and (2) when Z.sup.2 is a bond, R.sup.12 cannot be heteroaryl or heteroarylalkyl; Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms; R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cyclo-heteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.5 is independently alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, heteroarylcarbonyl, amino, alkyl-amino, arylamino, heteroarylamino, cycloalkyloxy, or cycloalkylamino, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, and alkylsulfinyl; R.sup.6 is hydrogen or C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkenyl; all optionally substituted with 1, 2, 3 or 4 groups which may independently be any of the substituents listed in the definition of R.sup.5 set out above; ##STR706## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; and N-oxides ##STR707## thereof; and pharmaceutically acceptable salts thereof. 2. The compound as defined in claim 1 having the formula ##STR708## 3. The compound as defined in claim 1 having the formula ##STR709## 4. The compound as defined in claim 1 wherein R.sup.1 is ##STR710## 5. The compound as defined in claim 4 wherein R.sup.1 is ##STR711## Z is a bond, O or S; R.sup.13, R.sup.14, R.sup.15 and R.sup.16 are each H or one of R.sup.15 and R.sup.16 and one of R.sup.13 and R.sup.14 are halogen; Z.sup.1 is a bond or C.dbd.O; R.sup.11 is alkylene or alkenylene; R.sup.12 --Z.sup.2 is ##STR712## R.sup.12a is alkyl, fluorinated lower alkyl or polyfluorinated lower alkyl. 6. The compound as defined in claim 1 wherein R.sup.1 is ##STR713## where R.sup.11 is alkylene or alkenylene; R.sup.12 is H, alkyl, alkenyl, aralkyl, aralkenyl; and R.sup.13 is H or F; and R.sup.15 is H or F; Z is O, S or a bond. 7. The compound as defined in claim 1 having the structure ##STR714## where Q is ##STR715## Z is a bond, O or S; where R.sup.5 is cycloalkyl, phenyl, aryl, heteroaryl, or cycloalkyl, phenyl, aryl or heteroaryl, independently substituted at the ortho position with alkyl, alkoxy, haloalkyl (optionally substituted with up to 5 halogens), trifluoromethyl, aryl, aryloxy, haloalkoxy (optionally substituted with up to 5 halogens), arylalkyl or arylalkoxy; R.sup.6 is H or CH.sub.3 ; R.sup.13 and R.sup.15 are independently H or F; Z.sup.1 is a bond; R.sup.11 is alkylene; R.sup.12 --Z.sup.2 is ##STR716## or Z.sup.2 is a bond and R.sup.12 is alkyl. 8. The compound as defined in claim 7 wherein R.sup.11 is --(CH.sub.2).sub.4 --, Z.sup.1 is a bond, and R.sup.12 --Z.sup.2 is ##STR717## 9. The compound as defined in claim 7 having the structure ##STR718## and R.sup.12 is trifluoromethylalkyl or alkyl. 10. The compound as defined in claim 7 having the structure ##STR719## where R.sup.12 is alkyl. 11. The compound as defined in claim 1 having the structure ##STR720## where Q is ##STR721## Z is a bond, O or S; where R.sup.5 is cycloalkyl, phenyl, aryl, heteroaryl, or cycloalkyl, phenyl, aryl or heteroaryl, independently substituted at the ortho position with alkyl, alkoxy, haloalkyl (optionally substituted with up to 5 halogens), trifluoromethyl, aryl, aryloxy, haloalkoxy (optionally substituted with up to 5 halogens), arylalkyl or arylalkoxy; R.sup.6 is H or CH.sub.3 ; R.sup.13 and R.sup.15 are independently H or F; Z.sup.1 is a bond; R.sup.11 is alkylene; ##STR722## R.sup.12 --Z.sup.2 is ##STR723## R.sup.12a is alkyl, fluorinated lower alkyl or polyfluorinated lower alkyl, or Z.sup.2 is a bond and R.sup.12 is alkyl. 12. The compound as defined in claim 1 which is 9-[4-[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]butyl]-N-propyl -9H-fluorene-9-carboxamide; 9-[4-[4-[[2-(phenoxyphenyl)carbonyl]amino]-1-piperidinyl]butyl]-N-propyl-9H -fluorene-9-carboxamide; 9-[4-[4-(benzoylamino)-1-piperidinyl]butyl]-N-propyl-9H-fluorene-9-carboxam ide; 9-[4-[4-(acetylamino)-1-piperidinyl]butyl]-N-propyl-9H-fluorene-9-carboxami de; 9-[4-[[4-[(1,1-dimethylethoxy)carbonyl]-amino]-1-piperidinyl]butyl]-2,7-dif luoro-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide; 9-[4-[4-[(2-phenoxybenzoyl)amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroet hyl)-9H-fluorene-9-carboxamide; 9-[4-[[4-(benzoylamino)-1-piperidinyl]-butyl]-2,7-difluoro-N-(2,2,2-trifluo roethyl)-9H-fluorene-9-carboxamide; 2,7-difluoro-9-[4-[[4-[(2-phenoxybenzolyl)-amino]-1-piperidinyl]butyl]-N-(2 ,2,2-trifluoro-ethyl)-9H-fluorene-9-carboxamide; 9-[4-[4-(benzoylamino)-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-9H-flu orene-9-carboxamide; [1-[4-[9-[(propylamino)carbonyl]-9H-fluoren-9-yl]butyl]-3-piperidinyl]carba mic acid, phenyl-methyl ester; 9-[4-[3-(benzoylamino)-1-piperidinyl]butyl]-N-propyl-9H-fluorene-9-carboxam ide; 9-[4-[[4-[(1,1-dimethylethoxy)carbonyl]-amino]-1-piperidinyl]butyl]-3,6-dif luoro-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide; 9-[4-[4-(benzoylamino)-1-piperidinyl]butyl]-3,6-difluoro-N-(2,2,2-trifluoro ethyl)-9H-fluorene-9-carboxamide; 3,6-difluoro-9-[4-[4-[(2-phenoxybenzoyl)-amino]-1-piperidinyl]butyl]-N-(2,2 ,2-trifluoroethyl-9H-fluorene-9-carboxamide; ##STR724## 9-[4-[4-[(phenoxycarbonyl)amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroet h yl)-9H-fluorene-9-carboxamide; 9-[4-[4-[[(phenylamino)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-triflu oroethyl)-9H-fluorene-9carboxamide; 9-[4-[4-[(phenylsulfonyl)amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethy l)-9H-fluorene-9-carboxamide; ##STR725## 9-[4-[4-[(2-phenoxybenzoyl)amino]-1-piperidinyl]-4-oxobutyl]-N-(2,2,2-trif l uoroethyl)-9H-fluorene-9-carboxamide; ##STR726## 9-[4-[4-[[(1,1-dimethylethoxy)carbonyl]-amino]-1-piperidinyl]pentyl]-N-(2, 2 ,2-trifluoroethyl)-9H-fluorene-9-carboxamide; 9-[4-[4-[[(2-phenyoxyphenyl)sulfonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-t rifluoroethyl)-9H-fluorene-9-carboxamide; 9-[2-[[[4-(benzoylamino)-1-piperidinyl]carbonyl]amino]ethyl]-N-(2,2,2-trifl uoroethyl)-9H-fluorene-9-carboxamide; 4-[(2-phenoxybenzoyl)amino]-1-piperidinecarboxylic acid, 2-[9-[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]ethyl ester; 4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinecarboxylic acid, 2-[9-[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]ethyl ester; 9-[4-[4-[(2-phenoxybenzoyl)amino]-1-piperidinyl]pentyl]-N-(2,2,2-trifluoroe thyl)-9H-fluorene-9-carboxamide; 9-[2-[[[4-[(2-phenoxybenzoyl)amino]-1-piperidinyl]carbonyl]amino]ethyl]-N-( 2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide; 4-(benzoylamino)-1-piperidinecarboxylic acid, 2-[9-(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]ethyl ester; 9-[4-[4-(benzoylamino)-1-piperidinyl]pentyl]-N-(2,2,2-trifluoroethyl)-9H-fl uorene-9-carboxamide; 9-[4-[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2 -trifluoroethyl)-9H-thioxanthene-9-carboxamide; 9-[4-[4-(benzoylamino)-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-9H-thi oxanthene-9-carboxamide; 9-[4-[4-[[(2-phenoxyphenyl)carbonyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-tr ifluoroethyl)-9H-thioxanthene-9-carboxamide; wherein for structures bearing only 2 single bonded substituents to N, the third substituent is always H, and for structures bearing an O or S with only one single bonded substituent, the second substituent is always H; and a pharmaceutically acceptable salt of any of the above and an N-oxide of any of the above. 13. The compound as defined in claim 1 which has the structure ##STR727## where R.sup.1 is a group of the structure ##STR728## R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylenealkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy, or cycloalkylalkyl, Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms; R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, carboxy, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.5 is independently alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, heteroarylcarbonyl, all optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, or arylsulfonylamino; R.sup.6 is hydrogen or C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkenyl; pharmaceutically acceptable salts thereof. 14. The compound as defined in claim 1 which has the structure ##STR729## where R.sup.1 is a fluorenyl-type group of the structure ##STR730## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O, S, ##STR731## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylenealkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the proviso that when R.sup.22 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR732## Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms; R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.5 is independently alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, or heteroarylcarbonyl, all optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, and arylsulfonylamino; R.sup.6 is hydrogen or C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkenyl; all optionally substituted with 1, 2 or 3 groups which may be any of the substituents listed in the definition of R.sup.5 set out above; ##STR733## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; or pharmaceutically acceptable salts thereof. 15. A method for preventing, or treating atherosclerosis; pancreatitis secondary to hypertriglyceridemia; hyperglycemia (1) by causing reduced absorption of dietary fat through MTP inhibition or (2) by lowering triglycerides through MTP inhibition or (3) by decreasing absorption of free fatty acids through MTP inhibition; or obesity by causing reduced malabsorption of dietary fat through MTP inhibition, in a mammalian species, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in claim 1. 16. A method of lowering serum lipid levels, cholesterol and/or triglycerides, or preventing and/or treating hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia, which comprises administering to a patient in need of treatment of a therapeutically effective amount of a compound as defined in claim 1. 17. The compound as defined in claim 7 wherein Q is ##STR734## Z is a bond; R.sup.5 is aryl or heteroaryl substituted at the ortho position with aryl or heteroaryl; R.sup.6 is H; R.sup.13 and R.sup.15 are each H; R.sup.12 --Z.sup.2 is ##STR735## 18. The compound as defined in claim 17 wherein R.sup.5 is ##STR736## and R.sup.11 is --(CH.sub.2).sub.4 --. 19. The compound as defined in claim 1 having the structure ##STR737## 20. The compound as defined in claim 1 which is cis-9-[4-[4-(2,3-dihydro-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-propyl-9 H-fluorene-9-carboxamide, N-oxide or cis-9-[4-[4[(2-phenoxybenzoyl)amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluo roethyl)-9H-fluorene-9-carboxamide, N-oxide. 21. A compound having the structure ##STR738## wherein Q is ##STR739## Z is a bond; R.sup.5 is phenyl substituted with aryl, wherein aryl is phenyl substituted with trifluoromethyl; R.sup.6 is H; R.sup.13 and R.sup.15 are each H; R.sup.12 --Z.sup.2 is ##STR740## R.sup.11 is (CH.sub.2).sub.4 ; Z.sup.1 is a bond or N-oxides ##STR741## thereof; or pharmaceutically acceptable salts thereof. 22. The compound as defined in claim 21 having the structure ##STR742## wherein alkyl is CH.sub.2, and aryl is phenyl substituted with CF.sub.3. 23. The compound as defined in claim 21 having the structure ##STR743## 24. A compound having the structure ##STR744## including the piperidine N-oxide thereof or a pharmaceutically acceptable salt thereof, Z is a bond; R.sup.5 is heteroaryl, aryl, cycloheteroalkyl or cycloalkyl, each R.sup.5 group being optionally substituted with 1, 2, 3 or 4 substituents which may be the same or different. 25. The compound as defined in claim 24 wherein the substituent on R.sup.5 is adjacent to the carbon attached to the ##STR745## group. 26. The compound as defined in claim 24 wherein R.sup.5 is phenyl substituted with heteroaryl, or phenyl which is substituted with haloalkyl or trifluoromethyl. 27. The compound as defined in claim 26 wherein R.sup.5 is ##STR746## 28. A compound which has the structure ##STR747## where Q is ##STR748## R.sup.1 is an indenyl-type group of the structure ##STR749## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond O, S, ##STR750## R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylene-alkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, heteroaryl, heteroarylalkyl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the provisos that (1) when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR751## or a bond; (2) when Z.sup.2 is a bond, R.sup.12 cannot be heteroaryl or heteroarylalkyl; (3) where R.sup.1 is indanyl E, if Z.sup.1 is a bond, then R.sup.12 --Z.sup.2 is other than alkyl or H; (4) where R.sup.1 is indenyl F, then Z.sup.2 is ##STR752## where R.sup.12 is other than alkoxy, or ##STR753## where R.sup.12 is other than alkyl; Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms; R.sup.13 and R.sup.14 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.15a and R.sup.16a are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl, or aryloxy; R.sup.5 is independently alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, heteroarylcarbonyl, amino, alkyl-amino, arylamino, heteroarylamino, cycloalkyloxy or cycloalkylamino, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl and alkylsulfinyl; R.sup.6 is hydrogen or C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkenyl; all optionally substituted with 1, 2, 3 or 4 groups which may independently be any of the substituents listed in the definition of R.sup.5 set out above; ##STR754## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; and N-oxides ##STR755## thereof; and pharmaceutically acceptable salts thereof. 29. The compound as defined in claim 28 wherein R.sup.1 is an indenyl-type group of the structure ##STR756## 30. The compound as defined in claim 28 which has the structure ##STR757## wherein R.sup.1 is an indenyl-type group of the structure ##STR758## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O, S, ##STR759## R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylenealkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, arylalkyl, arylalkenyl, cycloalkyl, trihaloalkyl, trihaloalkylalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, heteroaryl or heteroarylalkyl; with the provisos that (1) when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR760## or a bond; (2) when Z.sup.2 is a bond, R.sup.12 cannot be heteroaryl or heteroarylalkyl; (3) where R.sup.1 is indanyl E, if Z.sup.1 is a bond, then R.sup.12 --Z.sup.2 is other than alkyl; and (4) where R.sup.1 is indenyl F, then Z.sup.2 is ##STR761## where R.sup.12 is other than alkoxy, or ##STR762## where R.sup.12 is other than alkyl; Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms R.sup.13 and R.sup.14 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, carboxy, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.15a and R.sup.16a are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl, or aryloxy; R.sup.5 is alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, heteroarylcarbonyl, amino, alkylamino, arylamino, heteroarylamino, cycloalkyloxy or cycloalkylamino, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl or alkylsulfinyl; R.sup.6 is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkenyl; all optionally substituted with 1, 2, 3 or 4 groups which may independently be any of the substituents listed in the definition of R.sup.5 set out above; ##STR763## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; and N-oxides thereof; and pharmaceutically acceptable salts thereof. 31. A method for preventing or treating atherosclerosis; pancreatitis secondary to hypertriglyceridemia; hyperglycemia (1) by causing reduced absorption of dietary fat through MTP inhibition of (2) by lowering triglycerides through MTP inhibition or (3) by decreasing absorption of free fatty acids through MTP inhibition; or obesity by causing reduced malabsorption of dietary fat through MTP inhibition, in a mammalian species, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in claim 28. 32. A method of lowering serum lipid levels, cholesterol and/or triglycerides, or preventing and/or treating hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in claim 28. 33. The compound as defined in claim 30 wherein R.sup.1 is a group of the structure ##STR764## 34. A compound which has the structure ##STR765## wherein R.sup.1 is a group of the structure ##STR766## or Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O, S, ##STR767## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylenealkyene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, arylalkyl, arylalkenyl, cycloalkyl, trihaloalkyl, trihaloalkylalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, heteroaryl or heteroarylalkyl; with the provisos that (1) when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR768## or a bond, and (2) when Z.sup.2 is a bond, R.sup.12 cannot be heteroaryl or heteroarylalkyl; Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, carboxy, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.5 is alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, heteroarylcarbonyl, amino, alkylamino, arylamino, heteroarylamino, cycloalkyloxy, or cycloalkylamino, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, and alkylsulfinyl; R.sup.6 is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkenyl; all optionally substituted with 1, 2, 3 or 4 groups which may independently be any of the substituents listed in the definition of R.sup.5 set out above; ##STR769## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; and N-oxides thereof; and pharmaceutically acceptable salts thereof; ##STR770## 35. A method for preventing or treating atherosclerosis; or for preventing or treating pancreatitis secondary to hypertriglyceridemia; hyperglycemia (1) by causing reduced absorption of dietary fat through MTP inhibition or (2) by lowering triglycerides through MTP inhibition or (3) by decreasing absorption of free fatty acids through MTP inhibition; or obesity by causing reduced malabsorption of dietary fat through MTP inhibion, in a mammalian species, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound which has the structure ##STR771## where R.sup.1 is a fluorenyl-type group of the structure ##STR772## or R.sup.1 is an indenyl-type group of the structure ##STR773## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O, S, ##STR774## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylenealkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the proviso that when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, the Z.sup.2 is ##STR775## Z is a bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms; R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.15a and R.sup.16a are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl, or aryloxy; R.sup.5 is independently alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl or heteroarylcarbonyl, all optionally substituted through available carbon atoms with 1, 2 or 3 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl and arylsulfonylamino; R.sup.6 is hydrogen or C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkylenyl; all optionally substituted with 1, 2 or 3 groups which may be any of the substituents listed in the definition of R.sup.5 set out above; ##STR776## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; or pharmaceutically acceptable salts thereof. 36. A method for lowering serum lipid levels, cholesterol and/or triglycerides, or for preventing or treating hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia, in a mammalian species, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound which has the structure ##STR777## wherein R.sup.1 is a fluorenyl-type group of the structure ##STR778## R.sup.1 is an indenyl-type group of the structure ##STR779## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O, S, ##STR780## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylenealkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the proviso that when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, the Z.sup.2 is ##STR781## Z is a bond, O, S, or N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms; R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.15a and R.sup.16a are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl, or aryloxy; R.sup.5 is independently alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl or heteroarylcarbonyl, all optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl and arylsulfonylamino; R.sup.6 is hydrogen or C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkenyl; all optionally substituted with 1, 2 or 3 groups which may be any of the substituents listed in the definition of R.sup.5 set out above; ##STR782## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; or pharmaceutically acceptable salts thereof. 37. A method for preventing or treating atherosclerosis; or for preventing or treating pancreatitis secondary to hypertriglyceridemia; hyperglycemia (1) by causing reduced absorption of dietary fat through MTP inhibition or (2) by lowering triglycerides through MTP inhibition or (3) by decreasing absorption of free fatty acids through MTP inhibition; or obesity by causing reduced malabsorption of dietary fat through inhibition, in a mammalian species, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound which has the structure ##STR783## R.sup.1 is a fluorenyl-type group of the structure ##STR784## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O, S, ##STR785## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylenealkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, arylalkyl, arylalkyenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the proviso that when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR786## Z is a bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms; R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcabonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.5 is independently alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl or heteroarylcarbonyl, all optionaly substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl and arylsulfonylamino; R.sup.6 is hydrogen or C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkenyl; all optionally substituted with 1, 2 or 3 groups which may be any of the substituents listed in the definition of R.sup.5 set out above; ##STR787## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; or pharmaceutically acceptable salts thereof. 38. A method for lowering serum lipid levels, cholesterol and/or triglycerides, or for preventing or treating hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia, in a mammalian species, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound which has the structure ##STR788## R.sup.1 is a fluorenyl-type group of the structure ##STR789## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O, S, ##STR790## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylenealkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the proviso that when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR791## Z is a bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms; R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy; R.sup.5 is independently alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl or heteroarylcarbonyl, all optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl and arylsulfonylamino; R.sup.6 is hydrogen or C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkenyl; all optionally substituted with 1, 2 or 3 groups which may be any of the substituents listed in the definition of R.sup.5 set out above; ##STR792## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members, or pharmaceutically acceptable salts thereof. 